Norhammar A, et al. - In a real-world type 2 diabetes population, researchers examined cardiovascular (CV) safety and event rates of dapagliflozin vs other glucose-lowering drugs (GLDs). In Swedish nationwide healthcare registries, patients with new initiation of dapagliflozin and/or other GLDs were identified from 2013 to 2016. Subjects were included if they met the main criteria for inclusion of DECLARE-TIMI 58 (age ≥40 years and established CV disease or presence of multiple-risk factors, eg, men aged ≥55 years and women aged ≥60 years with hypertension or dyslipidemia). Investigators found that dapagliflozin was safe in terms of CV outcomes and resulted in lower event rates of hospitalization for heart failure and CV mortality vs other GLDs in a real-world population similar to those included in the DECLARE-TIMI 58 study.